Bibliometric Study on Belimumab for Systemic Lupus Erythematosus: Advances and Trends from 2015 to 2025

DOI: https://doi.org/10.62517/jmpe.202518505

Author(s)

Qi Li, Lin Kuang*

Affiliation(s)

School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China *Corresponding Author

Abstract

This study conducted a bibliometric analysis of research on belimumab in the treatment of systemic lupus erythematosus (SLE) between 2015 and 2025. A total of 709 relevant publications were identified during this decade, with an annual publication output showing steady growth and a notable increase observed in 2022, which correlates with updates in treatment guidelines and a rising interest in biologic agents. The United States contributed the highest number of publications (244), while China demonstrated a concentrated research effort in recent years. Among institutions, GlaxoSmithKline (GSK) produced the most publications (83), whereas institutions such as Karolinska Institute achieved higher average citation counts. Two core research teams were identified, and the phase III clinical trials led by Furie R formed the knowledge foundation of the field. Research hotspots included the BAFF mechanism, clinical trials, and end-stage renal disease. Recent studies have further revealed that beyond neutralizing BAFF, belimumab modulates multiple pathways, including interferon signaling, demonstrating multidimensional immunoregulatory effects and potential value in managing secondary antiphospholipid syndrome. Future research should focus on biomarker development, combination therapy strategies, and overcoming drug resistance mechanisms to enhance treatment precision and improve long-term patient outcomes.

Keywords

Belimumab; Systemic Lupus Erythematosus; Bibliometric; CiteSpace; VOSviewe

References

[1] Arnaud L, Chasset F, Martin T. Immunopathogenesis of systemic lupus erythematosus: An update. Autoimmun Rev. 2024;23(10):103648. [2] Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110-2121. [3] Oon S, Huq M, Golder V, Ong PX, Morand EF, Nikpour M. Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus. Ann Rheum Dis. 2019;78(5):629-633. [4] Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721-731. [5] Neupane B, Shukla P, Slim M, et al. Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks. Lupus Sci Med. 2023;10(1):e000907. [6] Siegel CH, Sammaritano LR. Systemic Lupus Erythematosus: A Review. JAMA. 2024;331(17):1480-1491. [7] Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. [8] Mullard A. FDA approves AstraZeneca's anifrolumab for lupus. Nat Rev Drug Discov. 2021;20(9):658. [9] Moysidou GS, Garantziotis P, Sentis G, et al. Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways. Ann Rheum Dis. 2025;84(2):262-273. [10]Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-1304. [11]Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15-29. [12]Yun Z, Duan L, Liu X, Cai Q, Li C. An update on the biologics for the treatment of antiphospholipid syndrome. Front Immunol. 2023;14:1145145. [13]Emmi G, Bettiol A, Palterer B, et al. Belimumab reduces antiphospholipid antibodies in SLE patients independently of hydroxychloroquine treatment. Autoimmun Rev. 2019;18(3):312-314. [14]Roveta A, Parodi EL, Brezzi B, et al. Lupus Nephritis from Pathogenesis to New Therapies: An Update. Int J Mol Sci. 2024;25(16):8981. Published 2024 Aug 18. [15]Karasawa K, Ogura S, Takabe T, et al. Successful Treatment with Belimumab in a Patient with Refractory Systemic Lupus Erythematosus after Initiation of Hemodialysis: Considering the Synergistic Effect of Belimumab and Immunological Burn-Out Phenomenon in End-Stage Renal Disease Patients on Hemodialysis. Blood Purif. 2022;51(2):182-188.